Back

Notification report


Full notification file


General information

Notification Number
B/NL/08/005

Member State to which the notification was sent
Netherlands

Date of acknowledgement from the Member State Competent Authority
30/05/2008

Title of the Project
A phase II, double blind randomized study to evaluate the immunogenicity of the therapeutic HIV-1 vaccine NYVAC-B versus placebo in chronic HIV-1 infected patients successfully treated with HAART (TheraVac-03)

Proposed period of release:
01/09/2008 to 01/04/2010

Name of the Institute(s) or Company(ies)
Academic Medical Center, Amsterdam;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Germany; France;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
Poxviridae, Subfamily: Chordapoxviridae, Genus: Orthopoxviruses, species: Vaccinia, strain: NYVAC (New York Vaccinia Virus)

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
NYVAC-BorthopoxvirusvacciniaN/ANYVACN/A

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known